Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Study of Tislelizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Patients, a Prospective Open Single-site Trial（TACBIN-01）

NCT04922047 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT04922047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Study of Tislelizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Patients, a Prospective Open Single-site Trial（TACBIN-01）
Lead sponsor
RenJi Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2021
Completion date
August 31, 2023
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antineoplastic agents, tislelizumab antineoplastic agents, immunological, urinary bladder diseases, urinary bladder neoplasms, urogenital neoplasms, urologic neoplasms